Zacks Upgrades Depomed To Outperform, $10 PT

August 10, 2011 9:09 AM | 6 seconds read |
Zacks Investment Research has upgraded Depomed DEPO from Neutral to Outperform with a $10 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsHealth CarePharmaceuticalsZacks investment research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!